Which of the following medication needs to be taken with 350 calories of food?

A. Lurasidone (Latuda) is a second-generation (atypical) antipsychotic, not a third-generation antipsychotic. It primarily blocks dopamine (D2) and serotonin (5-HT2A) receptors and is used to treat schizophrenia and bipolar depression.

B. Cariprazine (Vraylar) is a third-generation antipsychotic, functioning as a partial dopamine (D2/D3) and serotonin (5-HT1A) receptor agonist. It is used for schizophrenia, bipolar disorder, and major depressive disorder (MDD) adjunctive treatment.

C. Haloperidol (Haldol) is a first-generation (typical) antipsychotic, not a third-generation antipsychotic. It works by strongly blocking D2 receptors, leading to a high risk of extrapyramidal symptoms (EPS) but lower metabolic side effects compared to atypical antipsychotics.

D. Aripiprazole (Abilify) is a third-generation antipsychotic, known for its partial dopamine (D2) agonist properties. It has a lower risk of EPS and metabolic side effects compared to second-generation antipsychotics and is used for schizophrenia, bipolar disorder, and adjunctive treatment in depression.

A. Clozapine (Clozaril) does not require food for absorption, but it has a high risk of sedation, weight gain, and metabolic side effects. It also requires regular blood monitoring due to the risk of agranulocytosis.

B. Aripiprazole (Abilify) can be taken with or without food, as food does not significantly affect its absorption. It is a partial dopamine agonist, associated with a lower risk of weight gain and metabolic issues compared to other atypical antipsychotics.

C. Lurasidone (Latuda) must be taken with at least 350 calories of food to ensure proper absorption. Taking it on an empty stomach reduces its bioavailability, making it less effective. It is considered a weight-neutral antipsychotic and has a lower risk of metabolic side effects.

D. Haloperidol (Haldol) does not require food for absorption. It is a first-generation antipsychotic (FGA) with a high risk of extrapyramidal symptoms (EPS) but minimal metabolic effects.